for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Spring Bank Pharmaceuticals Inc

SBPH.OQ

Latest Trade

3.11USD

Change

-0.00(-0.00%)

Volume

20,533

Today's Range

2.83

 - 

3.15

52 Week Range

2.77

 - 

13.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.11
Open
2.83
Volume
20,533
3M AVG Volume
0.75
Today's High
3.15
Today's Low
2.83
52 Week High
13.23
52 Week Low
2.77
Shares Out (MIL)
16.46
Market Cap (MIL)
46.41
Forward P/E
-1.33
Dividend (Yield %)
--

Latest Developments

More

Spring Bank Pharmaceuticals Q2 Loss Per Share $0.28

Spring Bank Pharmaceuticals Inc Quarterly Loss Per Share $0.28

Spring Bank Announces FDA Acceptance Of IND Application For SB 11285

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Industry

Biotechnology & Drugs

Contact Info

35 Parkwood Dr Ste 210

+1.508.4735993

https://springbankpharm.com/

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.390

2017

-2.480

2018

-1.590

2019(E)

-2.114
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-52.91
Return on Equity (TTM)
-47.87

Latest News

Latest News

BRIEF-Spring Bank Pharma Appoints Timothy Clackson To Board

* SPRING BANK PHARMACEUTICALS APPOINTS TIMOTHY CLACKSON, PH.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11

* SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS

BRIEF-Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

* Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial

BRIEF-Spring Bank Pharmaceuticals may offer and sell shares of up to $50 mln common stock

* Spring Bank Pharmaceuticals Inc files to say may offer and sell shares of up to $50 million of common stock - SEC filing Source text: (http://bit.ly/2wpauAR) Further company coverage:

BRIEF-BVF Partners reports 5.1 pct passive stake in Spring Bank Pharmaceuticals as of Aug. 3

* BVF Partners L.P reports 5.1 percent passive stake in spring bank pharmaceuticals inc as of august 3, 2017 - SEC filing Source text (http://bit.ly/2vWRyKp) Further company coverage:

BRIEF-Spring Bank Pharmaceuticals posts Q2 loss per share $0.93

* Spring Bank Pharmaceuticals provides corporate update and reports second quarter 2017 financial and operational results

BRIEF-Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200​

* Spring Bank Pharmaceuticals Inc - announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining SB 9200

BRIEF-Spring Bank Pharma prices $37.5 mln public offering of common stock

* Spring bank pharmaceuticals prices $37.5 million public offering of common stock

BRIEF-Spring Bank Pharma announces proposed public offering of common stock

* Spring Bank Pharmaceuticals announces proposed public offering of common stock

BRIEF-Spring Bank Pharmaceuticals provides update on sting platform

* Spring Bank provides update on its next-generation sting platform and announces publication of an abstract at ASCO related to its lead sting agonist candidate, SB 11285

BRIEF-Spring Bank Pharmaceuticals files for mixed shelf of up to $150 mln - SEC filing

* Spring Bank Pharmaceuticals Inc files for mixed shelf of up to $150 million - SEC filing Source text: (http://bit.ly/2reHety) Further company coverage:

BRIEF-Spring Bank Pharma provides positive mid-stage data on Hep B drug

* Spring bank pharmaceuticals announces top-line results from the initial cohort of the phase 2a segment of the achieve trial, a global phase 2 clinical trial for chronic hepatitis b virus (hbv)

BRIEF-Spring Bank Pharmaceuticals posts Q1 loss per share $0.69

* Spring Bank Pharmaceuticals provides corporate update and reports first quarter 2017 financial and operational results

BRIEF-Spring Bank Pharmaceuticals Q4 loss per share $0.28

* Spring Bank Pharmaceuticals provides corporate update and reports 2016 financial and operational results

BRIEF-Spring Bank Pharma says announces financing of $15 mln

* Spring bank pharmaceuticals-proceeds to be used to fund further advancement of spring bank's pipeline of small molecule nucleic acid hybrid molecules

BRIEF-Spring Bank Pharma Q3 loss per share $0.53

* Spring bank pharmaceuticals-remain on track,look forward to reporting initial results from first dosing cohort in first half of next year for sb 9200

BRIEF-Spring Bank Pharmaceuticals presents data on Sting Agonist SB 11285

* Spring Bank Pharmaceuticals presents data on sting agonist sb 11285 at the AACR special conference on tumor immunology and immunotherapy Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up